# Lewy body dementia pathway and biomarker discovery

> **NIH NIH R56** · EMORY UNIVERSITY · 2020 · $667,958

## Abstract

Project Summary / Abstract
Lewy body dementia (LBD), which includes Parkinson disease dementia (PDD) and dementia with Lewy
bodies (DLB), is a common form of Alzheimer disease (AD)-related dementia that accounts for up to 30%
of all dementia cases. The pathological hallmarks of LBD are cortical α-synuclein aggregates in neuronal
cell body and neuronal processes termed Lewy bodies and Lewy neurites, respectively. Patients with LBD
suffer from cognitive impairment, neuropsychiatric symptoms, and Parkinsonian motor symptoms. Clinical
differentiation of DLB from PDD is based on an arbitrarily defined “one-year rule”: patients who develop
dementia before or within one year after the onset of motor symptoms are defined as DLB, whereas
patients who develop dementia after one year of the original diagnosis of Parkinson disease (PD) are
classified as PDD. Whether DLB and PDD are the same or different clinical syndromes remains hotly
debated, and our knowledge of the molecular commonalities and differences in the pathogenesis of these
two LBD subtypes is limited. Furthermore, LBD is underdiagnosed, due to the low sensitivity of the clinical
diagnosis criteria and challenges in clinical differentiation of LBD from AD. Currently, there is no reliable
biomarker for LBD diagnosis and no effective means of prevention or disease-modifying treatment,
highlighting the need to better understanding the pathogenesis of LBD. This project will address an
important yet understudied area of dementia research and use an innovative multiplex platform of
integrative proteomics, glycoproteomics, and glycomics to discover pathogenic pathways and molecular
targets for LBD diagnostic and therapeutic development. The proposed research will investigate and
uncover useful biological information stored in virtually unexplored, human LBD brain proteome,
glycoproteome, and glycome and identify molecules and pathways involved in LBD pathogenesis.
Furthermore, this project will use a systems biology approach to determine if the identified LBD-associated
molecules, networks, and pathways are similar to or distinct from those of Alzheimer disease. Results from
the proposed research will advance our knowledge of LBD pathogenesis and help accelerate the effort to
discover curative therapies for LBD and other neurodegenerative dementia including Alzheimer disease.

## Key facts

- **NIH application ID:** 10017801
- **Project number:** 5R56AG059714-02
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Lih-Shen Chin
- **Activity code:** R56 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $667,958
- **Award type:** 5
- **Project period:** 2019-09-15 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10017801

## Citation

> US National Institutes of Health, RePORTER application 10017801, Lewy body dementia pathway and biomarker discovery (5R56AG059714-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10017801. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*